Investigation of optimal regimen of Fulvestrant in patients with postmenopausal ER-positive advanced recurrent breast cancer
Phase of Trial: Phase IV
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 24 Aug 2018 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Results of subanalysis assessing factors associated with prolonged time to treatment failure with fulvestrant 500mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer, were presented at the 42nd European Society for Medical Oncology Congress.
- 17 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.